Antibody/ Non-Ab Manufacturing

Comprehensive Target Discovery and Validation at HDB–WuXi AppTec

by

Presented by: Shelly (Fang) Zhang, director II, exploration biology team leader, HD Biosciences–WuXi AppTec Novel target discovery and validation are the most crucial steps in successful drug development. Zhang presented her company’s evolving advanced gene manipulation (AGM) program, which is propelled by application of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein_9 (Cas9) technologies. The AGM platform supports target discovery and validation for conventional biologics and new modalities. She highlighted a number of technologies in development and their…

Enabling Pharma and Biotech Innovation Through an Open-Access Platform: Targeted Protein Degradation

by

Presented by: Dave Madge, vice president, research division, WuXi AppTec Madge described methods that his company applies to identify and evaluate bifunctional molecules that mediate targeted protein degradation (TPD). He pointed out that although much TPD research focuses on proteolysis targeting chimera (PROTAC) compounds, the tools used to identify such molecules also can be used to evaluate the therapeutic potential of other bifunctional molecules. Of particular interest are those that bring “housekeeping proteins” to disease-causing targets. More broadly, researchers are…

ROUNDTABLE: Bioconjugates – From Targets to Therapeutics

by

This podcast features: Chairperson: Alan C. Rigby, PhD, Vice President Research, ImClone Systems Speakers/Panelists: Dr James R. Prudent, President and Chief Executive Officer, Centrose Jason C. Brady, PhD, Director, Business Development, Conjugates and Cytotoxics, Lonza John Burt, Chief Executive Officer, PolyTherics Trishul P. Shah, Business Development Manager, PolyPeptide Group John M. Lambert, EVP & CSO, ImmunoGen, Inc     This podcast was recorded at the 2013 BioProcess Theater which took place at the 2013 BIO International Convention, April 22-25, 2013.…

Case Study: The Effect of Upstream Process Changes on HCP Composition and Detection

by

This podcast features: Dr. Kathrin Guenther, International Marketing Director, BioGenes     This podcast was recorded at the 2013 BioProcess Theater which took place at the 2013 BIO International Convention, April 22-25, 2013. The BioProcess Theater, a 50-seat amphitheater located on the exhibition floor at the heart of the BioProcess Zone, provided attendees with daily, complimentary opportunities to listen, learn, and interact with leading experts as they presented, discussed and debated the latest business and scientific trends impacting the development…

Optimized Solutions for Better Biologic Treatments

by

This podcast features: Dr. Greg Bleck, R&D Platform Director, Biologics, Catalent Pharma Solutions     This podcast was recorded at the 2013 BioProcess Theater which took place at the 2013 BIO International Convention, April 22-25, 2013. The BioProcess Theater, a 50-seat amphitheater located on the exhibition floor at the heart of the BioProcess Zone, provided attendees with daily, complimentary opportunities to listen, learn, and interact with leading experts as they presented, discussed and debated the latest business and scientific trends…

New Endotoxin Detection and Removal Methods in Downstream Processing of Biologics

by

This podcast features: Dr. Wolfgang Mutter, General Manager, Hyglos, GmbH     This podcast was recorded at the 2013 BioProcess Theater which took place at the 2013 BIO International Convention, April 22-25, 2013. The BioProcess Theater, a 50-seat amphitheater located on the exhibition floor at the heart of the BioProcess Zone, provided attendees with daily, complimentary opportunities to listen, learn, and interact with leading experts as they presented, discussed and debated the latest business and scientific trends impacting the development…